Synapse - Naiyer Rizvi

Results (166)

Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer

Journal Article

Gettinger, S. N.; Horn, L.; Gandhi, L.; Spigel, D. R.; Antonia, S. J.; Rizvi, N. A.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase 2 study of nivolumab (anti-programmed death-1 [PD-1]) in patients (pts) with advanced, refractory squamous (SQ) non-small cell lung cancer (NSCLC)

Meeting Abstract

Zalcman, G.; Rizvi, N. A.; Lena, H.; Wolf, J.; Mazieres, J.; Antonia, S. J.; Minenza, E.; Planchard, D.; Lestini, B. J.; Ramalingam, S. S.
Annals of Oncology (2015)

Fulltext@MSK | Save

Phase 2, open-label, international, non-comparative study of MEDI4736 in patients with locally advanced or metastatic, PD-L1 +, stage 3B-4 NSCLC who have received ≥2 prior systemic treatment regimens (ATLANTIC)

Meeting Abstract

Gray, J. E.; Garassino, M. C.; Vansteenkiste, J. F.; Ballas, M.; Jayawardene, D.; Stockman, P. K.; Powderly, J. D.; Rizvi, N.
Annals of Oncology (2015)

Fulltext@MSK | Save

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Journal Article

Rizvi, N. A.; Hellmann, M. D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J. J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T. S. ; more...
Science (2015)

Fulltext@MSK | Save

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial

Journal Article

Rizvi, N. A.; Mazières, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Horn, L.; Lena, H.; Minenza, E.; Mennecier, B.; more...
Lancet Oncology (2015)

Fulltext@MSK | Save

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)

Meeting Abstract

Brahmer, J.; Balmanoukian, A.; Goldberg, S.; Ou, S. H.; Blake-Haskins, A.; Karakunnel, J.; Stockman, P.; Rizvi, N.; Antonia, S.
Journal for ImmunoTherapy of Cancer (2014)

Fulltext@MSK | Save

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

Meeting Abstract

Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC